Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]
4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
4DMT Provides Company Update and Anticipated Development Milestones for 2026